: By acquiring GW, Jazz Pharmaceuticals significantly reduced its reliance on its flagship narcolepsy drug, Xyrem . The combined company now has a robust portfolio across neuroscience and oncology.
While the GW Pharmaceuticals platform adds significant value, an investment in Jazz Pharmaceuticals carries its own risks. The company took on substantial debt to finance the $7.2 billion acquisition, leading to a temporary increase in leverage. Potential investors should monitor the company's progress in paying down this debt and the continued clinical trial success of its pipeline. buy stock in gw pharmaceuticals
: The acquisition included GW’s cannabinoid product platform and clinical-stage programs for additional indications such as autism, schizophrenia, and multiple sclerosis-related spasticity. : By acquiring GW